RAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a report issued on Tuesday, Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.57) EPS, Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.62) EPS and FY2025 earnings at ($2.58) EPS.

A number of other research analysts also recently commented on the stock. Guggenheim downgraded shares of RAPT Therapeutics from a buy rating to a neutral rating in a research report on Friday, May 10th. Barclays downgraded shares of RAPT Therapeutics from an overweight rating to an equal weight rating and dropped their target price for the company from $13.00 to $4.00 in a research report on Friday, May 10th. Finally, Wolfe Research reaffirmed a peer perform rating on shares of RAPT Therapeutics in a research report on Tuesday, May 14th. Nine investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, RAPT Therapeutics presently has a consensus rating of Hold and a consensus price target of $21.57.

RAPT Therapeutics Stock Performance

RAPT opened at $2.30 on Tuesday. RAPT Therapeutics has a one year low of $2.12 and a one year high of $27.35. The company has a market cap of $80.27 million, a P/E ratio of -0.75 and a beta of 0.36. The business’s 50-day simple moving average is $2.95 and its 200-day simple moving average is $7.07.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. As a group, analysts predict that RAPT Therapeutics will post -2.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RAPT. Los Angeles Capital Management LLC purchased a new position in RAPT Therapeutics during the 4th quarter worth $233,000. Charles Schwab Investment Management Inc. grew its position in RAPT Therapeutics by 5.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 234,439 shares of the company’s stock worth $5,826,000 after purchasing an additional 12,650 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in RAPT Therapeutics during the 4th quarter worth $12,533,000. Chesapeake Capital Corp IL purchased a new position in RAPT Therapeutics during the 4th quarter worth $254,000. Finally, CenterBook Partners LP purchased a new position in RAPT Therapeutics during the 4th quarter worth $781,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.